SG190952A1 - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents
Compositions and methods for treating amyloid plaque associated symptoms Download PDFInfo
- Publication number
- SG190952A1 SG190952A1 SG2013042288A SG2013042288A SG190952A1 SG 190952 A1 SG190952 A1 SG 190952A1 SG 2013042288 A SG2013042288 A SG 2013042288A SG 2013042288 A SG2013042288 A SG 2013042288A SG 190952 A1 SG190952 A1 SG 190952A1
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- compositions
- associated symptoms
- amyloid plaque
- plaque associated
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title abstract 3
- 208000037259 Amyloid Plaque Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41906010P | 2010-12-02 | 2010-12-02 | |
| US201161548542P | 2011-10-18 | 2011-10-18 | |
| PCT/US2011/063121 WO2012075422A2 (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG190952A1 true SG190952A1 (en) | 2013-07-31 |
Family
ID=46172597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013042288A SG190952A1 (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Country Status (14)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2847218A4 (en) * | 2012-05-08 | 2015-12-30 | Univ Ramot | APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| CA2962969C (en) | 2014-09-30 | 2023-03-21 | Washington University | Tau kinetic measurements |
| WO2017192711A1 (en) * | 2016-05-03 | 2017-11-09 | University Of South Florida | Compositions and methods of modulating abeta protein |
| WO2018081642A1 (en) | 2016-10-28 | 2018-05-03 | Washington University | Anti-apoe antibodies |
| JP7280238B2 (ja) * | 2017-07-17 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法 |
| AU2020282792B2 (en) * | 2019-05-28 | 2025-12-04 | Banner Health | ApoE antibodies, fusion proteins and uses thereof |
| EP4419552A4 (en) * | 2021-10-19 | 2025-09-24 | Bioatla Inc | CONDITIONALLY ACTIVE PROTEINS FOR NEURODEGENERATIVE DISEASES |
| AU2023399623A1 (en) * | 2022-11-30 | 2025-07-03 | Bio-Techne Corporation | Natural killer cell engagers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2142300C (en) * | 1992-10-13 | 2005-08-23 | Allen D. Roses | Methods for detecting alzheimer's disease |
| EP1687336A2 (en) * | 2003-11-28 | 2006-08-09 | AstraZeneca AB | Antibodies |
| AU2005228764A1 (en) * | 2004-03-30 | 2005-10-13 | Renomedix Institute Inc. | Remedy for prion disease and method of producing the same |
| CA2643048A1 (en) * | 2006-02-21 | 2007-08-30 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
| CA2672581A1 (en) * | 2006-12-14 | 2008-06-19 | Forerunner Pharma Research Co., Ltd. | Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| CA2791648A1 (en) * | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
-
2011
- 2011-12-02 EP EP11844128.6A patent/EP2646053A4/en not_active Withdrawn
- 2011-12-02 CN CN2011800667946A patent/CN103338786A/zh active Pending
- 2011-12-02 US US13/990,777 patent/US20140037638A1/en not_active Abandoned
- 2011-12-02 JP JP2013542218A patent/JP2014502276A/ja active Pending
- 2011-12-02 KR KR1020137016719A patent/KR20140017513A/ko not_active Withdrawn
- 2011-12-02 MX MX2013006116A patent/MX2013006116A/es not_active Application Discontinuation
- 2011-12-02 SG SG2013042288A patent/SG190952A1/en unknown
- 2011-12-02 NZ NZ611614A patent/NZ611614A/en not_active IP Right Cessation
- 2011-12-02 AU AU2011336360A patent/AU2011336360A1/en not_active Abandoned
- 2011-12-02 BR BR112013013723A patent/BR112013013723A2/pt not_active IP Right Cessation
- 2011-12-02 WO PCT/US2011/063121 patent/WO2012075422A2/en not_active Ceased
- 2011-12-02 CA CA2819679A patent/CA2819679A1/en not_active Abandoned
- 2011-12-02 RU RU2013130002/10A patent/RU2013130002A/ru not_active Application Discontinuation
-
2013
- 2013-05-31 ZA ZA2013/03996A patent/ZA201303996B/en unknown
-
2016
- 2016-08-22 US US15/243,495 patent/US20160355581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ611614A (en) | 2015-07-31 |
| CN103338786A (zh) | 2013-10-02 |
| BR112013013723A2 (pt) | 2019-09-24 |
| WO2012075422A2 (en) | 2012-06-07 |
| US20160355581A1 (en) | 2016-12-08 |
| CA2819679A1 (en) | 2012-06-07 |
| ZA201303996B (en) | 2015-10-28 |
| EP2646053A2 (en) | 2013-10-09 |
| EP2646053A4 (en) | 2014-05-28 |
| MX2013006116A (es) | 2013-10-17 |
| AU2011336360A1 (en) | 2013-07-04 |
| KR20140017513A (ko) | 2014-02-11 |
| RU2013130002A (ru) | 2015-01-10 |
| US20140037638A1 (en) | 2014-02-06 |
| WO2012075422A3 (en) | 2012-10-04 |
| JP2014502276A (ja) | 2014-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG190952A1 (en) | Compositions and methods for treating amyloid plaque associated symptoms | |
| UA109123C2 (uk) | Пробіотична композиція для застосування в лікуванні запалення кишечнику | |
| UA107600C2 (uk) | АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ | |
| MX2018009945A (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
| CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
| MY163275A (en) | Ibat inhibitors for the treatment of liver diseases | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| NI201200171A (es) | Anticuerpos hacia gdf8 humano | |
| CO6571886A2 (es) | Antagonistas de pcsk9 | |
| UA109271C2 (uk) | Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми | |
| EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| EA201291031A1 (ru) | Способ лечения ожирения с применением антиоксидантных модуляторов воспаления | |
| MX343640B (es) | Promotor de osteogenesis. | |
| PH12012501680A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
| PT2621520E (pt) | Composições de colagenase g e colagenase h para o tratamento de doenças que envolvem alterações de colagénio | |
| GB201109238D0 (en) | Antibodies | |
| TN2015000277A1 (en) | Bmp-6 antibodies | |
| SG178596A1 (en) | Methods of treatment using anti-oxidized ldl antibodies | |
| MX2014006337A (es) | Composiciones de proteina del gen 3 de bacteriofago y sus usos como agentes de union amiloides. | |
| EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
| WO2010102248A3 (en) | Molecular tweezers for the treatment of amyloid-related diseases |